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Abstract
The hyaluronan (HA) receptor for endocytosis (HARE) mediates
the endocytotic clearance of HA and other glycosaminoglycans
from lymph and blood. Two isoforms of human HARE, 315- and
190-kDa, are highly expressed in sinusoidal endothelial cells of
liver, lymph node, and spleen; HARE is also in specialized cells
in the eye, heart, brain, and kidney. Here we determined whether
HA binding to HARE initiates intracellular signaling in Flp-In 293
cells stably expressing either the 315- and 190-kDa HARE or the
190-kDa HARE alone. HARE was co-immunoprecipitated with extracellular signal-regulated kinase 1 and 2 (ERK1/2), c-Jun N-terminal protein kinase (JNK), and p38 members of the mitogen-activated protein kinase signaling cascade. ERK phosphorylation
increased in a dose- and time-dependent manner when HA was
added to cells expressing full-length or 190-kDa HARE, but not
cells with vector-only or a HARE(ΔLink) construct with greatly decreased (~90%) HA uptake. HA did not induce phosphorylation of
JNK or p38. A maximum increase in phospho-ERK1/2 occurred
within 30 min at 5 μg/ml HA, and the response was dampened at
>20 μg/ml HA. HA binding did not increase the level of HARE-ERK
complexes, but did increase HARE phosphorylation. These findings demonstrate a novel functional response, when HARE binds
HA, that leads to activation of ERK1/2, important mediators of intracellular signal transduction.
Abbreviations: HA, hyaluronan; aa, amino acids; BSA, bovine serum albumin; CS, chondroitin sulfate; ECM, extracellular matrix; ERK,
extracellular signal-regulated kinase; EV, empty vector; GAG, glycosaminoglycan; HARE, HA receptor for endocytosis; hHARE, human
HARE; HRP, horseradish peroxidase; JNK, c-Jun N-terminal kinase;
MAP kinase, mitogen-activated protein kinase; mAb, monoclonal antibody; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; pAb, polyclonal antibody; pERK, phosphorylated
ERK; pJNK, phosphorylated JNK; p-p38 kinase, phosphorylated p38
kinase; RHAAM, receptor for HA-mediated mobility; tERK, total ERK
protein; tJNK, total JNK protein; 190-HARE, the 190-kDa HA receptor
for endocytosis; 315-HARE, the 315-kDa HA receptor for endocytosis

H

yaluronan (HA), a nonsulfated GAG made up of repeating β(1,4)-d-glucuronic acid-β(1,3)-N-acetyl-d-glu
cosamine disaccharide units, is present in the ECM of all vertebrate tissues.
HA plays important roles in matrix assembly, cell differentiation, migration, morphogenesis, and wound healing (1–3).

Elevated levels of HA are associated with various pathologies,
such as arthritis, inflammation, and cancer (4–7). The average adult human contains ~15 g of HA, of which ~5 g is synthesized and degraded daily in tissues throughout the body
(1). Most of the HA and CS types released from tissues during this turnover process are ultimately cleared from the circulation and lymph fluid by the HA Receptor for Endocytosis (HARE) (8, 9), also known as Stabilin-2 (10) or FEEL-2 (11).
Human HARE is encoded by the 180-kb STAB2 gene, found
on chromosome 12, consisting of 69 exons, and is abundantly
expressed in the sinusoidal cells of lymph nodes, liver, and
spleen (8–10, 12, 13). Rat and hHARE in these tissues are present as two isoforms (8, 12, 13), e.g. hHARE isoforms are ~190
and ~315 kDa. Although HARE in the sinusoidal cells of liver
and lymph node has a known endocytic clearance function,
it may also have other, not yet described, functions. HARE is
also expressed in corneal and lens epithelium, in mesenchymal cells of heart valves, in ependymal cells lining the ventricles in the brain, in epithelial cells covering the renal papillae
(14), and in oviduct (15). The functions of HARE in these latter
tissues are unknown and might be different from local GAG
clearance.
We have stably expressed the recombinant 190-kDa (16)
and full-length 315-kDa (17) HARE proteins in Flp-In 293
cell lines, using cDNA derived from human lymph node.
These Flp-In cell lines have one unique, recombinase-mediated integration site. The full-length 315-kDa HARE is a type
I membrane protein that contains a 2458-aa extracellular domain (with four cysteine-rich fasciclin/epidermal growth
factor-like domains of unknown function and a LINK domain), a transmembrane domain, and a 72-aa cytoplasmic
domain. The 190-kDa HARE is identical to the C-terminal
1417 aa of the 315-kDa HARE and is derived from the fulllength protein by proteolytic cleavage (12, 13, 17).
HARE binds and mediates internalization of HA as well
as four types of CS (16, 17) via the clathrin-coated pit-mediated endocytic pathway (18, 19). Recent studies demonstrate
that endocytosis plays an important role in the activation
and propagation of signaling pathways, such as ERK 1 and 2
(20, 21), which are members of the mitogen-activated protein
(MAP) kinase cascade. Multiple reports have documented
that HA binding to HA receptors CD44 and RHAMM
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(CD168) triggers signal transduction events through activation of ERK1/2 (22, 23). MAP kinases are important mediators of signal transduction and play key roles in the regulation of many cellular processes, such as cell growth and
proliferation, differentiation, and apoptosis.
In mammalian cells, three major groups of MAP kinases
have been identified: ERK, JNK, and p38 (24). A common
feature of the three MAP kinases is that they are typically organized together in three-kinase modules. The usual ERK
signaling cascade proceeds through activation of Raf, MEK,
and then ERK1/2. MAP kinases are stimulated via receptor
and nonreceptor protein kinases and G-protein-coupled receptors. MAP kinase cascades are differentially activated by
a variety of extracellular stimuli, including growth factors,
cytokines, stress, and ECM components (23, 24). After activation, MAP kinases are translocated to the nucleus where they
phosphorylate transcription factors that regulate expression of immediate-early response genes. This cascade of responses results in altered levels of proteins that lead to functional and morphological changes of the cell.
HA signaling through CD44 and RHAMM involves several signaling pathways, including the MAP kinase cascade, that lead to HA-dependent functions in various cells
and tissues; e.g. HA binding to CD44 may regulate hematopoiesis by activating the p38 MAP kinase (25). In addition,
HA-CD44 interactions affect matrix metabolism in articular chondrocytes via activation of transcription factor NFκB
and the p38 MAP kinase (26, 27). Furthermore, CD44 and
RHAMM play pivotal roles in activating oncogenic signaling and HA-mediated tumor cell functions. Overexpression
of RHAMM strongly correlates with overexpression of Ras
and ERK, and could be a useful prognostic marker for breast
cancer progression (28). CD44 and RHAMM form complexes
with ERK1/2 in invasive breast cancer cells with high basal
motility (29). An HA-CD44-mediated oncogenic mechanism
also occurs in ovarian cancer progression (30).
In the present study, we found that the receptor HARE
was able to mediate HA-dependent intracellular signal
transduction and increase the phosphorylation of HARE and
ERK1/2. This unexpected cell signaling activity of HARE indicates that this receptor is involved in multiple intracellular
routing or signaling pathways.

Experimental Procedures
Materials, Solutions, and Buffers—Tris-HCl, glycine, and
acrylamide were obtained from Research Products International (Mt. Prospect, IL); SDS, Nonidet P-40, and methanol
were from EMD (Gibbstown, NJ). Protease inhibitor mixture (catalog number P8340 containing 4-(2-aminoethyl)benzenesulfonyl fluoride, aprotinin, leupeptin, bestatin, pepstatin A, and E-64), sodium pyrophosphate, sodium fluoride,
sodium orthovanadate, benzamidine, 2-mercaptoethanol,
EGTA, EDTA, and Tween 20 were obtained from Sigma.
HA, prepared by bacterial fermentation, was obtained from
Genzyme Corp. (Cambridge, MA). 125I-Iodine (100 mCi/
ml; specific activity of >0.6 TBq/mg) in NaOH was from GE
Healthcare. 125I-HA, modified at the reducing end was prepared as described previously (31), Flp-In 293 cells, fetal bovine serum, Dulbecco’s modified Eagle’s medium, and hygromycin B were from Invitrogen. Affinity purified goat
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anti-V5 pAb was obtained from Bethyl Labs (Montgomery,
TX). Rabbit pAbs against pERK (Thr(P)202 and Tyr(P)204)
1 and 2 (44- and 42-kDa, respectively), ERK1/2, pJNK
(Thr(P)183 and Tyr(P)185), JNK, p-p38 MAP kinase (Thr(P)180
and Tyr(P)182), p38 MAP kinase, and PD 98059 (a MEK inhibitor) were obtained from Cell Signaling Technology (Beverly, MA). Protein A/G Plus-agarose, goat anti-rabbit IgGHRP, goat anti-mouse IgG-HRP, donkey anti-goat IgG-HRP,
goat anti-actin (I-19) pAb, antERK2 conjugated to agarose,
and rabbit anti-ERK2 (C-14, which also recognizes ERK1)
pAb were from Santa Cruz Biotechnology (Santa Cruz, CA).
Mouse anti-Tyr(P) (PY-20) mAb was from BD Biosciences
(San Jose, CA). Western Lightning Chemiluminescence Reagent Plus was from PerkinElmer Life Sciences. Nitrocellulose membranes were from Schleicher & Schuell (Dassel,
Germany). Classic blue autoradiography film BX was from
MIDSCI (St. Louis, MO). Coomassie Protein Assay Reagent
was obtained from Pierce. TBS contains 20 mm Tris-HCl, pH
7.0, 150 mm NaCl. TBST is Tris-buffered saline with 0.1%
(v/v) Tween 20. Lysis Buffer contains 20 mm Tris, pH 7.2,
1 mm sodium orthovanadate, 3 mm benzamidine, 2 mm sodium pyrophosphate, 5 mm sodium fluoride, 2 mm EGTA, 5
mm EDTA, 1 μg/ml of protease mixture inhibitor, and 0.5%
(v/v) Nonidet P-40.
Cell Lines Expressing 315- or 190-kDa HARE—The construction of 190- and 315-HARE expression vectors, and
the selection and characterization of stable Flp-In 293 cell
transfectants are described in detail by Harris et al. (16, 17).
To make the 190-HARE(Δlink) construct, a single primer
(5′-CCACTTCCAGGATACCACTGTTCGGATGAAAGATGTGAACTGCACC-3′) was used with the 190-HARE wild
type template to delete the coding region of the 93-aa Link
domain. Mutagenesis was performed with pfu Ultra (Stratagene) in an EriComp thermal cycler (18 cycles: 94 °C, 30 s; 62
°C, 30 s; and 71 °C, 1 min/plasmid kb). After these reactions,
both template and new plasmids were ethanol precipitated
(0.1 volume of 3 m potassium acetate, pH 5.5, 2 volumes of
95% ethanol), resuspended in 17 μl of H2O, 2 μl of NEB4 buffer, and 2.5 units of DpnI to digest template plasmids, while
retaining the intact mutant plasmids. After overnight incubation at 37 °C, the digestion mixtures were heated to 95 °C
for 10 min and immediately transformed into TOP10 supercompetent Escherichia coli cells. Bacterial cells were screened
by a Miniprep procedure, PCR, and sequencing to confirm
the desired mutation. Plasmids containing correct mutations,
open reading frames, and promoter regions were used to
make stable cell lines as described (16, 17). Cells stably expressing recombinant full-length 315-HARE also produce
the 190-HARE from the full-length protein by proteolysis.
The cloned and amplified open reading frame for the fulllength 315-HARE from pooled lymph node cDNAs (Marathon system; Clontech) was inserted into expression vector
pcDNA5/RFT/V5-His-TOPO. Except for the secretion signal, the same strategy was used for the 190-HARE. Only stable clones with a single plasmid integrated into the correct,
unique recombinase-mediated chromosomal site were selected and used, as described (16, 17).
Cell Lines and Cell Stimulation—Cells expressing fulllength 315-HARE, 190-HARE alone, Flp-In 293 parent cells,
or cells transfected with vector alone were grown in Dulbecco’s modified Eagle’s medium with 8% fetal bovine serum
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supplemented with 100 μg/ml hygromycin B for at least 2
days prior to experiments, to 80–90% confluence. Cells were
washed 2 times with phosphate-buffered saline and incubated in fresh medium without serum for 1 h at 37°C prior
to starting the experiment. Based on preliminary results (not
shown) the 1-h incubation in serum-free medium was optimal for observing subsequent HA-induced protein phosphorylation. The cells were washed, received fresh serumfree Dulbecco’s modified Eagle’s medium, and incubated
with HA at various concentrations for various times at 37 °C,
as indicated. All experiments used non-animal-derived HA
with a weight-average molar mass of 580 kDa. For ERK inhibition assays, after the 1-h incubation in serum-free medium, cells were pretreated with different concentrations of
the MEK inhibitor PD 98059 for 30 min and then treated with
5 or 10 μg/ml of HA for 20 min at 37 °C. Cells were then
collected by scraping, washed with ice-cold phosphate-buffered saline, and centrifuged at 1,600 × g for 5 min. Cell pellets were incubated with mixing for 1 h at 4 °C in Lysis Buffer, and the lysates were cleared by centrifugation at 14,000 ×
g for 10 min at 4 °C. The cell lysate supernatants were used
for experiments after determination of protein content (32).
Immunoblot Analysis—Cell lysates (25 μg of protein) were
subjected to 5 or 10% SDS-PAGE (33) and electrotransfer to nitrocellulose membranes (34) using a mini-transfer unit (Bio-Rad) for 2 h at 4°Cat 80 V in 25 mm Tris-HCl,
pH 7.4, 190 mm glycine, and 20% (v/v) methanol. To confirm that any differences in band intensity following Western blot analysis were not due to differences in protein loading, the membranes were first stained with 0.1% Ponceau S
water-soluble stain and photographed. Membranes were
then washed 4 times for 5 min each with water and incubated with 5% nonfat dry milk in TBST for 1 h at room temperature. The washed membranes were incubated overnight at 4 °C with pAbs (diluted 1:1000 in 5% milk/TBST)
to pERK1/2, or ERK1/2, or Abs (diluted 1:1000 in TBST containing 5% BSA) to pJNK, JNK, p-p38 MAP kinase, or p38
MAP kinase. After washing 3 times for 10 min each in TBST,
the membranes were incubated with anti-rabbit IgG-HRP
conjugate, diluted 1:2000 in TBST containing either 5% milk
(for ERK Abs) or 5% BSA (for JNK and p38 Abs) for 1 h at
room temperature.
For Western blot analysis using anti-V5 pAb, membranes
were incubated in TBST containing 1% BSA for 1 h at room
temperature, washed, incubated with 1:4000 goat anti-V5 Ab
for 1 h, washed, and incubated with secondary anti-goat Ab
conjugated to HRP diluted 1:6000. We used 5% BSA-containing buffers for blocking nonspecific binding sites and for incubations with anti-Tyr(P) (PY20) mAb, diluted 1:1000. After four washes for 10 min each in TBST, ECL and exposure
to film was utilized for detection according to the manufacturer’s instructions. Autoradiography films were scanned
into digital files, and band densities were quantified, using
an Alpha Innotech FluoroChem 8000 imaging system (Alpha Innotech Corporation, San Leandro, CA), as integrated
densitometry values (i.e. the sum of all pixel values minus
background correction). The results are expressed as a ratio,
e.g. pERK divided by tERK.
In Figures 1, 2, 5, 6, 7, and 8, the blots shown in the same
panel were successively stripped and stained with different
Abs to normalize the results. After one round of detection,
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blots were stripped by washing with water and incubating
in 62.5 mm Tris-HCl, pH 6.7, 100 mm β-mercaptoethanol, 2%
SDS at 55 °C for 30 min. After five washings for 10–15 min
each with TBST, the blots were reprobed with a different Ab
as above. As a control for gel loading accuracy, bound Abs
were stripped from the blot and the blot was reprobed with
anti-actin Ab. The ECL and film method was utilized for detection. Figures show a representative set of Western blots
from two or usually three independent experiments, which
gave similar results.
Immunoprecipitation Assays—Rabbit pAb against ERK2,
JNK, p38, or mouse anti-Tyr(P) mAb (1 μg/ml) were added
to cell lysates (200 μg of protein) and incubated with rotation for 2 h at 4 °C. Immune complexes were then collected
by adding 20 μl of 250 μg/ml Protein A/G Plus Agarose
and incubated with rotation overnight at 4 °C. The resin was
washed three times with cold phosphate-buffered saline, the
pellet was resuspended in 30 μl of 2× Laemmli sample buffer (33), incubated for 3 min at 90 °C, and subjected to SDSPAGE and Western blot analysis. We also used three mAbs
(numbers 30, 154, and 159) raised against rat HARE (9)
that cross-react with both the 315- and 190-kDa HARE (12).
HARE was immunoprecipitated, as described above, using
mAb 30 alone or mAbs 30, 154, and 159 attached to CNBr-activated Sepharose (8, 12, 16, 17). ECL and film was utilized
for detection.
HA Endocytosis Assays—Cells were grown to ~90% confluence, washed, and incubated for 1 h at37 °Cin Dulbecco’s
modified Eagle’s medium with 0.5% BSA to allow clearance
of serum-derived GAGs bound to cell surface HARE. The
cells were washed and then incubated with 1.5 μg/ml 125IHA with and without a 100-fold excess of unlabeled HA (to
assess specific binding) for 4 h. The cells were then chilled,
washed, lysed, and radioactivity and protein were determined (16, 17).
Statistical Analysis—Data from experimental groups (usually n = 3) were compared by the unpaired Student’s t test
using SigmaPlot version 10 (Systat Software, Inc., Point Richmond, CA) and are presented as the mean ± S.E. Values of p
≤ 0.05 were considered statistically significant.

Results
HA Treatment Induces HARE Phosphorylation—First, we
wanted to determine whether HARE is phosphorylated
on Tyr, because many endocytic, recycling receptors contain Tyr(P) (35, 36), and it is unlikely that HARE would be
an exception. In addition, the cytoplasmic domain of HARE
has 4 Tyr that could be phosphorylated (e.g. as assessed by
NetPhos 2.0). To test this, we used anti-Tyr(P) mAb to purify Tyr(P)-containing proteins and then Western blot analysis with anti-V5 Ab to detect co-immunoprecipitated recombinant HARE (Figure 1A). The 315-kDa HARE was detected
among Tyr(P)-containing proteins from 315-HARE cells and
190-kDa HARE was detected in cells expressing 190-HARE
alone (Figure 1A). Some experiments showed the minor 190kDa band present in 315-HARE cells. Neither HARE band
was present in cells containing empty vector (EV). Also, no
immunoreactive bands were observed at the HARE band
positions in control samples using non-immune mouse IgG
(not shown).
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Figure 2. Expression of MAP kinases in 315-HARE and 190-HARE
cells. Cells expressing 315-HARE, 190-HARE, or EV alone were
grown to confluence, washed, scraped, and lysed as described under
“Experimental Procedures.” Lysate samples were analyzed by 10%
SDS-PAGE and Western blot analysis using anti-pERK (A), anti-pJNK
(B), or anti-p-p38 (C) Ab, all of which detect activated (phosphorylated)
forms of ERK1/2 (pERK1/2), JNK (pJNK), and p38 (p-p38) MAP kinases. The same blots were stripped and reprobed with anti-tERK1/2
or anti-t-p38 Ab, all of which detect total protein.

Figure 1. HA induces Tyr phosphorylation of HARE. A, cells expressing 315-HARE, 190-HARE, or EV alone were cultured in T-25 flasks
until confluent, washed, scraped, and lysed. Cell lysates (100 μg of
protein) were immunoprecipitated (IP) with anti-Tyr(P) mAb and the
immune complexes were subjected to 5% SDS-PAGE and Western
blot (WB) analysis using anti-V5 pAb as described under “Experimental Procedures.” Cells expressing 315-HARE (B) or 190-HARE (C)
cDNA were grown until confluent, washed, incubated for 1 h in medium without serum, and then incubated with (HA) or without (Ctr)5 μg/
ml HA for 20 min. The cells were lysed and 200 μg of total lysate protein was immunoprecipitated with anti-HARE mAb-30. Immune complexes were collected and subjected to 5% SDS-PAGE and Western
analysis using anti-Tyr(P) mAb as described under “Experimental Procedures.” The same blots in B and C were reprobed with anti-V5 Ab
(D and E, respectively). Immunopurification using non-immune mouse
IgG served as another control in B–E. The solid and open arrows indicate the positions of the 315-HARE and 190-HARE, respectively.

We then tested whether HA treatment induced HARE
phosphorylation in cells expressing 315- or 190-HARE by immunoprecipitating HARE with mAb 30 and probing blots
with anti-Tyr(P) Ab (Figure 1, B and C). Cells were incubated
for 1 h in serum-free medium, incubated with or without 5
μg/ml of HA for 20 min, and HARE was then immunoprecipitated. Exposing cells to HA increased the amount of Tyr(P) in
HARE almost 5-fold compared with untreated cells. This occurred in 315-HARE cells containing both the 315- and 190kDa HARE (Figure 1B) or in 190-HARE cells expressing just
the 190-kDa HARE (Figure 1C). When these latter two immunoblots were stripped and reprobed using Ab against the Cterminal V5 epitope (Figure 1, D and E), no differences in the
amount of receptor expression were detected, confirming that
exposure to HA enhanced the Tyr phosphorylation of HARE.
Basal Phosphorylation of MAP Kinases Increases in 315HARE or 190-HARE Cells—We addressed the possibility that
MAP kinases, which are Ser/Thr protein kinases, could be
phosphorylated in cells expressing HARE. The basal phosphorylation level of MAP kinases in Flp-In 293 cells stably
expressing the full-length 315- and 190-kDa HARE or the
190-kDa HARE alone were determined by Western blot analysis using three phospho-specific anti-MAP kinase Abs that
detect the phosphorylated (active) forms of ERK1 (44 kDa)
and ERK2 (42 kDa) proteins (Figure 2A), JNK1 (54 kDa) and
JNK2 (46 kDa) proteins (Figure 2B), or p38 (38 kDa) MAP kinase (Figure 2C). Cells expressing either 315-HARE or 190HARE showed 3–4-fold increases in phosphorylated ERK1

and ERK2 compared with cells transfected with the EV. In
contrast, we did not find increases in JNK or p38 phosphorylation in cells expressing 190- or 315-HARE. We detected
no differences in the protein levels of the three MAP kinases
when immunoblots were reprobed using Abs that recognize
total ERK, JNK, or p38 proteins.
HARE and ERK1/2 Form Complexes—We examined whether
there is a physical interaction between HARE and ERK1 or
ERK2 in cells expressing 315- and 190 kDa-HARE or 190-kDa
HARE alone by immunoprecipitating either ERK or HARE
protein from cell lysates. The associated proteins were then
cross-probed in Western blots. The 315- and 190-kDa HARE
were both detected in blots of anti-ERK immunoprecipitates
(Figure 3A). Consistent with this result, ERK1 and ERK2 were
detected in anti-HARE immunoprecipitates probed with antiERK Ab (Figure 3B). Cells transfected with EV did not show
bands (Figure 3, A and B) at the position of either HARE, indicating that the observed complexes were specific and dependent on the presence of both HARE and ERK. Also, no
HARE-containing immunoreactive material was observed
in control samples when mouse IgG was used for immunopurification or immunoblotting (not shown). Stimulation of
190-HARE cells with HA did not increase the level of HAREERK complexes, as assessed by co-immunoprecipitation using
Ab against tERK, which recognizes active pERK plus inactive
non-phosphorylated ERK (Figure 3C). Taken together, these
results clearly show that HARE and ERK1 and ERK2 are associated with each other as a stable complex in cells expressing
either the full-length HARE or the 190-kDa isoform.
HARE and JNK or p38 MAP Kinase Also Form Complexes—
We determined whether there is also an association between
HARE and the other MAP kinases, JNK and p38. We performed immunoprecipitations with anti-JNK or anti-p38 Ab
followed by immunoblotting with anti-V5 Ab using 315- or
190-HARE cells. Association of HARE with JNK (Figure 4A)
and p38 (Figure 4B) was detected in cells expressing either
the full-length HARE or 190-kDa HARE alone. No similar
MAP kinase complexes were found in cells transfected with
EV. These results demonstrate that both JNK and p38 physically interact with HARE.
HA Stimulates ERK Phosphorylation in a Time-dependent
Way—To examine the activation of ERK1 and ERK2, cells expressing 315- and 190-kDa HARE, 190-kDa HARE only, or
EV were incubated for 1 h at 37 °C without serum and then
with 10 μg/ml HA for various times. Extracts were assessed
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HARE-mediated Stimulation of ERK
Phosphorylation by HA Is Dose-dependent—We used increasing HA concentrations to assess the concentration dependence of ERK activation in 190-kDa
HARE cells (Figure 6). As HA increased
between 0.1 and 5 μg/ml, pERK1 and
pERK2 increased until reaching a maximum at 5 μg/ml (Figure 6, A and C).
The response then declined at 10 or 20
μg/ml HA. Total ERK1 and ERK2 protein levels remained the same. In contrast, cells transfected with EV showed
Figure 3. HARE and ERK form complexes in 315-HARE and 190-HARE cells. Cells expressing
315-HARE, 190-HARE, or EV were grown to confluence, washed, scraped, lysed, and centrifuged, no activation of ERK1/2 in the presence
and samples were subjected to immunoprecipitation (IP) with anti-tERK (A) Ab or anti-HARE (B) of HA (Figure 6, B and D). DensitometmAbs 30, 154, and 159. Immune complexes were collected and subjected to SDS-PAGE and ric analyses of 190-HARE cell samples
Western blot (WB) analysis using anti-V5 or anti-tERK Ab, as indicated. Lysates from 315-HARE (Figure 6C) revealed a significant (p =
cells served as a positive control (Ctr) to identify the positions of 315- and 190-kDa HARE (A), or 0.03) 2.5-fold increase in pERK1/2 at
pERK1 and pERK2 (B). The solid and open arrows in A indicate the positions of 315-HARE and the lowest HA dose (0.1 μg/ml) used.
190-HARE, respectively. C, cells expressing 190-HARE or EV were incubated for 1 h in serumCompared with untreated 190-HARE
free medium, and then incubated as indicated in the presence or absence of 5 μg/ml HA for 20
min at 37 °C. Cell lysates were immunoprecipitated with anti-ERK2 Ab conjugated to agarose, and cells, the pERK to tERK ratio was inanalyzed as above. As a negative control, release of interfering Ab was estimated by treating rab- creased about 3-fold (p = 0.001) at 1 μg/
bit IgG-agarose with Laemmli buffer (33).
ml HA, 4-fold (p = 0.006) at 5 μg/ml,
and 2-fold (p = 0.05) at 10 μg/ml (Figure 6C). A similar dose
response with a maximum increase of pERK1/2 at 5 μg/ml
was observed in cells expressing full-length 315-kDa HARE
cDNA (not shown).
HA Has No Effect on Phosphorylation of JNK and p38 MAP
Kinase—Next, we determined if there was also activation of
JNK and p38 MAP kinase, or if there was a differential activation of ERK kinases, compared with the other two MAP
kinases. In contrast to the ERK1/2 results, no time-(Figure 7,
A and C) or dose-dependent (Figure 7, B and D) increases in
phosphorylation were observed for either JNK or p38 MAP
kinase in 190-HARE or 315-HARE (not shown) cells treated
with HA. These results indicate that HA binding to HARE
mediates a specific response to activate ERK in cells expressing the full-length 315-HARE or 190-HARE alone.
Figure 4. Detection of HARE-JNK and HARE-p38 MAP kinase comHA-HARE-mediated ERK Phosphorylation Is Blocked by a MEK
plexes. Confluent cultures of 315-HARE, 190-HARE, or EV cells were
Inhibitor—We tested the effect of PD 98059, a specific inhibiwashed and scraped, and lysates were immunoprecipitated (IP) with
tor of MEK, which is the upstream kinase activator of ERK, on
anti-tJNK (A) or anti-t-p38 MAP kinase Ab (B). Immune complexes
HA-induced phosphorylation of ERK in 190- and 315-HARE
were collected and subjected to SDS-PAGE and Western blot (WB)
cells. MEK inhibition decreased HA-stimulated pERK levels,
analysis using anti-V5 Ab. Lysates from 315-HARE cells (Ctr) served
to identify 315- and 190-kDa HARE. The solid and open arrows indiwithout affecting the levels of the two ERK or the two HARE
cate the positions of 315-HARE and 190-HARE, respectively.
proteins (Figure 8A). HA-induced ERK phosphorylation was
greatly inhibited by 50 μm PD 98059 and the pERK to tERK
ratio was lower than that observed in the absence of inhibitor
by Western blot analysis for HA-induced changes in ERK ac(Figure 8B). Quantification of results from two dose-response
tivation (i.e. phosphorylation). Other results (not shown) inexperiments showed that PD 98059 at 0.1 and 1 μm had no or
dicated that the 1-h incubation in serum-free medium was
little effect on ERK phosphorylation, whereas 10 μm caused
optimal for detection of subsequent HA-induced protein phosa ~30% reduction of ERK activation (Figure 8C). HA-induced
phorylation. Cells expressing 315- or 190-kDa HARE that were
phosphorylation of ERK was ~70% inhibited by 50 μm PD
exposed to HA showed time-dependent changes in pERK1 and
98059, reaching essentially the basal level of pERK1/2 in unpERK2. After 30 min, pERK1 and pERK2 in 315-HARE (Figure
treated cells. The results support the conclusion that HA bind5, A and D) and 190-HARE (Figure 5, B and E) cells reached a
ing to HARE stimulates pERK production by MEK.
maximum that was almost 4- and 8-fold greater, respectively,
HARE-mediated ERK Activation Requires Its HA-binding Acthan the time 0 values. Over the next 30 min, pERK1/2 declined
tivity—To confirm that HA binding to HARE is responsible
to baseline levels, due to dephosphorylation of the proteins. Elfor the intracellular signaling events that activate ERK1/2,
evated pERK levels in 315- and 190-HARE cells were statistiwe assessed the effect of HA on cells expressing a 190-HARE
cally significant at 5 (p = 0.02, p = 0.01, respectively), 15 (p = 0.02,
mutant lacking the 93-aa Link domain (Figure 9). Compared
p = 0.07, respectively), and 30 min (p = 0.01, p = 0.05, respecwith cells with WT HARE, cells expressing HARE(ΔLink)
tively). Control cells transfected with EV, not expressing HARE,
were 90% inhibited in their ability to bind and endocytose
did not show increased pERK1/2 levels (Figure 5, C and F).
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and signaling processes. The signaling
response is not due to a contaminant
in the HA preparations, nor is it due
to different ligand-binding regions of
HARE that interact with other endogenous ligands (e.g. acetylated-LDL) on
the cell surface or in the medium.

Discussion
The results presented here show
for the first time that HA binding to
HARE stimulates intracellular signal transduction pathways associated
with cellular responses to ECM components. The Link domains in many
HA-binding proteins and receptors are
directly responsible for their HA binding activity (37–39). Deleting the Link
Figure 5. HA induces time-dependent changes in ERK phosphorylation in 315- and 190-HARE cells. domain of HARE almost completely
Cells expressing 315-HARE (A), 190-HARE (B), or EV (C) were grown to confluence and washed. Af- eliminated its ability to mediate HA
ter a 1-h incubation in serum-free medium at 37 °C, the cells were incubated in the presence or ab- binding and endocytosis, and to stimsence of 10 μg/ml HA for 0–30 min as indicated. Lysate samples were then subjected to 10% SDSulate intracellular ERK activation in
PAGE and Western analysis with Ab against pERK1/2 (top panels). The same blots were stripped
and reprobed with Ab against tERK1/2 protein (middle panels), and then anti-actin (bottom panels). stably transfected cells.
HA binding induces a time- and
Blots from independent experiments were scanned, densitometry analyses performed, and the normalized results are presented in D (315-HARE, n = 3), E (190-HARE, n = 3), and F (EV, n = 2) as the dose-dependent increase in the phosmean ± S.E. of the pERK to tERK ratio (compared with untreated cells at zero time, as 100%).
phorylation of ERK1 and ERK2 in cells
stably expressing either the 315- and
190-HARE or the 190-HARE alone. After incubation with
HA for 30 min, phosphorylated ERK1 and ERK2 reached
maximum levels in both cell types. A maximum increase of
pERK1/2 occurred at 5 μg/ml HA. In contrast to ERK activation, HA (up to 20 μg/ml for 60 min) did not stimulate
phosphorylation of two other MAP kinases, JNK and p38. In
the absence of added HA, both HARE isoforms are found in
stable complexes with all three MAP kinases. HA binding to
190-HARE cells did not increase the amount of ERK-HARE
complexes, indicating that HA binding to HARE might induce activation of ERK1/2 in pre-existing complexes. HA
binding to HARE also resulted in increased phosphorylation
of HARE on Tyr. HA-induced ERK phosphorylation was
also diminished ~70% by the MEK inhibitor PD 98059 (50
μm), which prevents activation (i.e. phosphorylation) of ERK
by MEK in other cell types (40, 41).
HARE was first characterized as an endocytic clearance
receptor that mediates the systematic removal of HA and
Figure 6. HA induces dose-dependent changes in ERK phosphorylaCSs from the circulatory and lymphatic systems (1, 42).
tion in 190-HARE cells. Cells stably expressing 190-HARE (A and C)
HARE is highly expressed in the sinusoidal cells of lymph
or EV (B and D) were grown to confluence, washed, and incubated for
nodes, which are the initial and primary sites for the clear1 h in serum-free medium at 37 °C. The cells were then incubated for
ance of high molar mass HA (>106 Da) and CS; about 85%
20 min at 37 °C with the indicated concentrations of HA, chilled, lysed,
of the HA entering nodes is degraded. A second HA/CS
and samples were analyzed by 10% SDS-PAGE and Western blotting
clearance site utilizes HARE in the sinusoidal endothelial
with Ab against pERK1/2. The same blots were successively reprobed
with anti-tERK1/2 Ab to detect total protein and then anti-actin Ab, as incells of liver, accounting for degradation of the remaindicated. The blots from independent experiments were scanned, densiing (~15%) smaller HA that leaves lymph nodes and entometry analysis performed, and the normalized results are presented
ters the vascular system (43, 44). HARE is also highly exas the mean ± S.E. of the pERK to tERK ratio (compared with untreated
pressed in spleen, where it may play an as yet unknown
cells, as 100%) for 190-HARE (C, n = 3) and EV (D, n = 2) cells.
role in the immune system, and to a lesser extent in other
125I-HA (Figure 9A). In experiments to assess ERK1/2 actissues, as noted under Introduction. In addition to HA
and multiple CS types, HARE/Stabilin-2 specifically rectivation in response to HA (as in Figures 5 and 6), the
ognizes advanced glycation end products (45), and we reHARE(ΔLink) cells showed no detectable ERK phosphorylacently discovered that the 190-HARE and 315-HARE are
tion response, even up to 20 μg/ml HA (Figure 9B). Thus, HA
also endocytic receptors for heparin (E. N. Harris, J. A. Weibinding to HARE initiates the intracellular ERK activation
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Figure 7. HA does not induce time- or dose-dependent changes in the
phosphorylation of JNK or p38 MAP kinase. Cells stably expressing
190-HARE were grown to confluence, washed, incubated in serumfree medium for 1 h at 37 °C, and then incubated either with 10 μg/
ml HA for the indicated times (A and C) or with the indicated amounts
of HA for 1 h (B and D). The cells were then lysed and samples were
analyzed by SDS-PAGE and Western blotting using Ab against either pJNK (A and B) or p-p38 MAP kinase (C and D). The membranes
were stained with anti-tJNK, successively stripped, and probed with
anti-t-p38 and then anti-actin Ab, as indicated.

gel, and P. H. Weigel J. Biol. Chem. [April 22, 2008] doi:
10.1074/jbc.M710360200).
Thus, HARE can bind and internalize four different
classes of ligands. Additionally, ongoing studies indicate
that the cytoplasmic domain, although small, contains at
least three redundant motifs for targeting HA-HARE complexes to coated pits (M. S. Pandey, E. N. Harris, J. A. Weigel,
and P. H. Weigel, unpublished data). Deletion of any of these
three motifs only partially decreases the rate of endocytosis,
indicating that HARE complexes might have multiple intracellular routing pathways. Because HARE is expressed in tissues that are not involved in the systemic clearance of HA or
CS, we have suspected that HARE may have functions other
than simply ligand clearance. This study supports the possibility that the HARE isoforms allow cells to sense and respond to a variety of different ECM molecules.
The HA field has been energized in recent years by the
elucidation of HA-dependent signaling pathways, providing
novel insights into the biological functions of this ECM molecule (23, 46–48). Binding of HA to CD44 or RHAMM stimulates intracellular signal transduction, by activating protein
phosphorylation, and modifies cell-cell and cell-matrix interactions (22, 23). HA activates several protein Tyr and Ser/Thr
kinases (including MAP kinases, protein kinase C, focal adhesion kinase, and Src protein Tyr kinase) and thereby promotes
the expression of specific proteins involved in ECM remodeling and cell differentiation (23). The biology of HA now encompasses a wider array of cellular behaviors, in addition to
its important and well established ECM structural roles.
Our experiments used non-animal-derived HA with
a weight-average molar mass of 580 kDa for several reasons. Using HA made by bacterial fermentation avoids artifacts due to contaminating mammalian (e.g. umbilical cordderived) or other eukaryotic (e.g. chicken-derived) proteins

Figure 8. The MEK inhibitor PD 98059 inhibits HA- and HARE-mediated ERK phosphorylation. Cells stably expressing 315-HARE (A
and C) or 190-HARE (B) were grown to confluence, washed, and incubated in serum-free medium for 1 h at 37 °C. A, the 315-HARE cells
were incubated with different amounts of PD 98059 for 30 min, as indicated, and then treated for 20 min with 10 μg/ml HA. The cells were
chilled, lysed, and samples subjected to 10% SDS-PAGE and Western blot analysis using anti-pERK1/2. The same blot was successively
stripped and reprobed with anti-tERK and then anti-actin Ab, as indicated. A parallel 5% SDS-PAGE was run with the same amount of
protein and Western blot analysis was performed using anti-V5 Ab to
identify the 315-HARE (solid arrow) and 190-HARE (open arrow) proteins. B, 190-HARE cells were grown to confluence, washed, incubated in serum-free medium for 1 h at 37 °C and then incubated, as indicated, with or without PD 98059 for 30 min and then without or with
5μg/ml HA for 20 min. Cell lysates were subjected to SDS-PAGE and
Western blot analysis using anti-pERK1/2, and the blot was stripped
and reproved with anti-tERK and then anti-actin Abs, as indicated. C,
two sets of blots from independent experiments using 315-HARE cells
were scanned, analyzed by densitometry, and the normalized results
are expressed as the mean ± S.E. ratio of pERK to tERK; the value
with no inhibitor present is set to 100%.

bound to the HA. We used the same size HA in previous endocytosis studies of the recombinant human 190- and 315HARE and know it is bound with high affinity and efficiently
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Figure 9. HA endocytosis and ERK activation are greatly decreased
in a 190-HARE(ΔLink) mutant. Cells expressing WT or (ΔLink) mutant
190-HARE or EV were grown and preincubated as described in the
legend to Figure 6. A, the cells were incubated with 125I-HA for 4 h at
37°C to assess specific endocytosis. Values are the mean ± S.E. (n
= 9–12) percent of endocytosis compared with WT (100%), from four
independent experiments. B, ERK phosphorylation was assessed as
described in the legend to Figure 6 after incubation with the indicated
concentrations of HA for 20 min. Lysate samples were then subjected
to 10% SDS-PAGE and Western analysis with Ab against pERK1/2
(top panel). The same blot was stripped and reprobed with Ab against
tERK1/2 protein (middle panel), and anti-actin (bottom panel).

internalized (16, 17). Finally, it makes sense that cells may
need to detect and respond to smaller HA fragments with
more urgency than native high mass HA. Under pathological
conditions lower molar mass HA can accumulate and affect
inflammation, angiogenesis, wound healing and cancer (49).
For example, HA of molar masses up to 950 kDa induces Tyr
phosphorylation in NCI-H82 cells stably transfected with human CD44E cDNA (50).
MAP kinases are a family of evolutionary well conserved
proteins that are expressed in all eukaryotic cells. They are
components of signaling pathways that relay, amplify, and
integrate signals from a variety of extracellular stimuli, thus
controlling the genomic and physiological response of a cell
to its environment (24, 28). The three major groups of MAP
kinases, ERK, JNK, and p38, are Ser/Thr protein kinases.
Distinct MAP kinase cascades occur in selective activation
responses to different extracellular stimuli, leading to a wide
variety of cellular function changes. In this study we found
that basal pERK1/2 levels in cells stably expressing the fulllength HARE or 190-kDa HARE were >3 times higher than
in EV cells. In contrast, there was no difference in the basal
phosphorylation status of JNK or p38 MAP kinase. Furthermore, co-immunoprecipitation results demonstrated an as-
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sociation of HARE not only with ERK but also with the two
other members of the MAP kinase family. Formation of intracellular multiprotein complexes is a mechanism by which
cells integrate and transmit different signals. We observed
basal levels of HARE-ERK, HARE-JNK, and HARE-p38 complexes, although only ERK1/2 were activated upon HARE
binding of HA. We do not know if all three MAP kinases simultaneously associate with HARE to create quaternary
complexes, but this may be likely. RHAMM also associates
with ERK, but not with JNK or p38 (51).
Protein phosphorylation, specifically on Ser, Thr, and Tyr
residues, is one of the most important and widespread posttranslational modifications. Protein phosphorylation regulates many metabolic pathways and also regulates the activation of signal transduction cascades that in turn regulate
gene expression and cellular functions (52). To understand
the molecular basis of these regulatory mechanisms, it is
necessary to identify the key protein phosphorylation sites.
The cytoplasmic domain of the 190- and 315-HARE (Tyr2480–
Leu2551) contains four Tyr, seven Ser, one His, and five Thr
residues (10, 12), although only residues Ser2497, Ser2537,
Thr2523, Tyr2519, and Tyr2531 are predicted (by NetPhos 2.0)
to be phosphorylated. As expected, the cytoplasmic domain
contains several candidate Tyr residues whose phosphorylation may be HA-mediated. To identify key HARE residues
in the HARE cytoplasmic domain required for formation of
HARE-ERK complexes and to mediate the HA-dependent
activation of ERK-dependent signal transduction pathways,
we are creating stable cell lines expressing 190-HARE variants with defined aa substitutions or deletions.
In summary, we present evidence that HA binding to
hHARE induces Tyr phosphorylation of HARE and selectively induces the phosphorylation of ERK1 and ERK2 in a
dose- and time-dependent manner. In contrast, HA binding
to HARE does not induce the phosphorylation of JNK or p38
MAP kinase. The conclusion that HA-induced ERK phosphorylation is mediated by MEK, an upstream ERK kinase,
is supported by the inhibitory effect of the MEK inhibitor PD
98059. Our results indicate that HA binding to hHARE regulates intracellular Tyr and Ser/Thr protein kinases. This
study uncovers a novel and previously unknown role for
hHARE in cell signaling, particularly in activating the ERK
signaling pathway.
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